USANA Health Sciences (NYSE: USNA) reported Q4 EPS of $1.32, $0.01 worse than the analyst estimate of $1.33. Revenue for the quarter came in at $299 million versus the consensus estimate of $307.69 million.

“USANA finished the year with another quarter of solid results, bolstered by our annual China National Sales Meeting in Macau and a few targeted product promotions in select markets,” said Kevin Guest, Chief Executive Officer.

GUIDANCE:

USANA Health Sciences sees FY2019 EPS of $5.25-$5.55, versus the consensus of $5.12. USANA Health Sciences sees FY2019 revenue of $1.25-1.3 billion, versus the consensus of $1.2 billion.

For earnings history and earnings-related data on USANA Health Sciences (USNA) click here.